Innovative and passionate; that's how we describe our biotech companies. From cutting-edge biopharmaceutical therapies to bioinformatics, we support our clients’ pursuit of excellence. Through their relentless drive to innovate, we work to protect pivotal intellectual property, navigate regulatory environments, and advise on financing strategy.
Industry Highlights
Celebrating our founders’successes
2026
Cognito Therapeutics Announces Oversubscribed $105 Million Series C
Neurotechnology
2026
Soley Therapeutics Announces $200 Million Series C Financing
Biotechnology, Drug Discovery
2025
Foresight Diagnostics Announces Acquisition by Natera
Cancer Diagnostics
2025
Denali Therapeutics Announces $200 Million Public Offering
Biopharmaceutical, Biotechnology
2025
Enliven Therapeutics Announces $230 Million Public Offering
Biopharmaceutical
2024
Kumquat Biosciences and Takeda Enter into Strategic Collaboration and Global License Agreement
Biotechnology
2023
DTx Pharma Announces Acquisition by Novartis
Biotechnology
2023
XinThera Announces Acquisition by Gilead Sciences
Biotechnology
2023
Aspect Biosystems Announces $2.7 Billion Collaboration with Novo Nordisk
Biotechnology
2022
Tenaya Therapeutics Raises Approximately $75 Million in Public Stock Offering
Biotechnology
2022
GSK Completes Acquisition of Sierra Oncology
Biopharmaceutical
2022
Arcellx, Inc. Raises $124 Million IPO
Biotechnology
2021
Ventyx Biosciences Closes IPO at $175 Million
Biotechnology, Pharmaceuticals
2021
Tenaya Therapeutics Completes IPO Worth $207 Million
Biotechnology
2021
Kinnate Biopharma Inc. Raises $276 Million IPO
Drug Discovery, Pharmaceuticals
2020
ALX Oncology Holdings Inc. Closes IPO at $186 Million
Immuno-Oncology
2020
ORIC Pharmaceuticals Raises $138 Million IPO
Pharmaceuticals
2020
Applied Molecular Transport Closes IPO at $154 Million